Home  |  Contact

Cellosaurus U-87MG ATCC (CVCL_0022)

Cell line name U-87MG ATCC
Synonyms U-87MG; U-87 MG; U87 MG; U-87-MG; U87-MG; U87MG; U-87; U87; 87 MG; 87MG
Accession CVCL_0022
Resource Identification Initiative To cite this cell line use: U-87MG ATCC (RRID:CVCL_0022)
Comments Problematic cell line: Misidentified. This cell line is not the original glioblastoma cell line established in 1968 at the University of Uppsala. As described in PubMed=27582061 it is most probably also a glioblastoma cell line but whose origin is unknow. See U-87MG Uppsala (Cellosaurus=CVCL_GP63) for the original U-87MG cell line.
Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Part of: ENCODE project common cell types; tier 3.
Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00535.
Population: Caucasian.
Doubling time: 39 hours (PubMed=9842975); 72 hours (PubMed=25984343); ~34 hours (PBCF).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Cell surface proteome.
Omics: CNV analysis.
Omics: CRISPR phenotypic screen.
Omics: Deep antibody staining analysis.
Omics: Deep exome analysis.
Omics: Deep proteome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: Genome sequenced.
Omics: HLA class I peptidome analysis by proteomics.
Omics: shRNA library screening.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Sequence variations
  • Mutation; HGNC; 5382; IDH1; None_reported; -; Zygosity=- (PubMed=19435942).
  • Mutation; HGNC; 7765; NF1; Simple; p.Phe1247Ilefs*18 (c.3739_3742delTTTG) (3737_3740delTGTT); ClinVar=VCV000420078; Zygosity=Heterozygous (Cosmic-CLP; DepMap).
  • Mutation; HGNC; 9588; PTEN; Simple; c.209+1G>T; ClinVar=VCV000229705; Zygosity=Homozygous; Note=Splice donor mutation (PubMed=9090379; Cosmic-CLP; DepMap).
  • Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700).
  • Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (Cosmic-CLP; DepMap).
HLA typing Source: PubMed=25960936
Class I
HLA-AA*02:01,02:01
HLA-BB*44:02,44:02
HLA-CC*05:01,05:01
Class II
HLA-DQDQA1*01:02,01:02
DQB1*06:02,06:02
HLA-DRDRB1*15:01,13:07

Source: PubMed=26589293
Class I
HLA-AA*02:01,02:01
HLA-BB*44:02,44:02
HLA-CC*05:01,05:01

Source: PubMed=27412690
Class I
HLA-AA*02:01:01
HLA-BB*44:02
HLA-CC*05:01:01
Genome ancestry Source: PubMed=30894373

Origin% genome
African0.69
Native American0
East Asian, North3.92
East Asian, South0
South Asian0
European, North72.18
European, South23.21
Disease Glioblastoma (NCIt: C3058)
Glioblastoma (ORDO: Orphanet_360)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_D1RF (Abcam U-87MG ABCA1 KO)CVCL_D1RG (Abcam U-87MG ABL1 KO)CVCL_D1RH (Abcam U-87MG ADAM10 KO)
CVCL_D1RI (Abcam U-87MG ADRB3 KO)CVCL_D1RJ (Abcam U-87MG AKR1C1 KO)CVCL_D1RK (Abcam U-87MG ALDH1A1 KO)
CVCL_D1RL (Abcam U-87MG APP KO)CVCL_D1RM (Abcam U-87MG ASNS KO)CVCL_D1RN (Abcam U-87MG ASS1 KO)
CVCL_D1RP (Abcam U-87MG ATP1A3 KO)CVCL_D1RQ (Abcam U-87MG BACE2 KO)CVCL_D1RR (Abcam U-87MG BEST1 KO)
CVCL_D1RS (Abcam U-87MG BIN1 KO)CVCL_D1RT (Abcam U-87MG CACNA2D1 KO)CVCL_D1RU (Abcam U-87MG CAV1 KO)
CVCL_D1RV (Abcam U-87MG CD82 KO)CVCL_D1RW (Abcam U-87MG CHI3L1 KO)CVCL_D1RX (Abcam U-87MG CHRM3 KO)
CVCL_D1RY (Abcam U-87MG CHRNA5 KO)CVCL_D1RZ (Abcam U-87MG CNTNAP1 KO)CVCL_D1S0 (Abcam U-87MG CSF1 KO)
CVCL_D1S1 (Abcam U-87MG CST3 KO)CVCL_D1S2 (Abcam U-87MG CTSD KO)CVCL_D1S3 (Abcam U-87MG CYP1B1 KO)
CVCL_D1S4 (Abcam U-87MG DCX KO)CVCL_D1S5 (Abcam U-87MG DLG4 KO)CVCL_D1S6 (Abcam U-87MG DRD1 KO)
CVCL_D1S7 (Abcam U-87MG DYRK1A KO)CVCL_D1S8 (Abcam U-87MG ECE1 KO)CVCL_D1S9 (Abcam U-87MG EGFR KO)
CVCL_D1SA (Abcam U-87MG ELAVL3 KO)CVCL_D1SB (Abcam U-87MG ELAVL4 KO)CVCL_D1SC (Abcam U-87MG ENPP2 KO)
CVCL_D1SD (Abcam U-87MG ERN1 KO)CVCL_D1SE (Abcam U-87MG FGFR1 KO)CVCL_D1SF (Abcam U-87MG FLT1 KO)
CVCL_D1SG (Abcam U-87MG FMR1 KO)CVCL_D1SH (Abcam U-87MG FN1 KO)CVCL_D1SI (Abcam U-87MG FOS KO)
CVCL_D1SJ (Abcam U-87MG FOXA2 KO)CVCL_D1SK (Abcam U-87MG FOXC2 KO)CVCL_D1SL (Abcam U-87MG G3BP1 KO)
CVCL_D1SM (Abcam U-87MG GABBR1 KO)CVCL_D1SN (Abcam U-87MG GABRA1 KO)CVCL_D1SP (Abcam U-87MG GAD1 KO)
CVCL_D1SQ (Abcam U-87MG GBA KO)CVCL_D1SR (Abcam U-87MG GFAP KO)CVCL_D1SS (Abcam U-87MG GJA1 KO)
CVCL_D1ST (Abcam U-87MG GLUL KO)CVCL_D1SU (Abcam U-87MG GRIA1 KO)CVCL_D1SV (Abcam U-87MG GRIA2 KO)
CVCL_D1SW (Abcam U-87MG GRIA4 KO)CVCL_D1SX (Abcam U-87MG GRIN2A KO)CVCL_D1SY (Abcam U-87MG GRIN2B KO)
CVCL_D1SZ (Abcam U-87MG GRM1 KO)CVCL_D1T0 (Abcam U-87MG GRM3 KO)CVCL_D1T1 (Abcam U-87MG GRM5 KO)
CVCL_D1T2 (Abcam U-87MG GRM7 KO)CVCL_D1T3 (Abcam U-87MG GSK3A KO)CVCL_D1T4 (Abcam U-87MG GSN KO)
CVCL_D1T5 (Abcam U-87MG HTR7 KO)CVCL_D1T6 (Abcam U-87MG HTT KO)CVCL_D1T7 (Abcam U-87MG IDH1 KO)
CVCL_D1T8 (Abcam U-87MG IL13RA2 KO)CVCL_D1T9 (Abcam U-87MG ITPR1 KO)CVCL_D1TA (Abcam U-87MG KCND2 KO)
CVCL_D1TB (Abcam U-87MG KCNJ6 KO)CVCL_D1TC (Abcam U-87MG KEAP1 KO)CVCL_D1TD (Abcam U-87MG L1CAM KO)
CVCL_D1TE (Abcam U-87MG LAMP1 KO)CVCL_D1TF (Abcam U-87MG LAMP2 KO)CVCL_D1TG (Abcam U-87MG LGI1 KO)
CVCL_D1TH (Abcam U-87MG LOXL1 KO)CVCL_D1TI (Abcam U-87MG MAP2 KO)CVCL_B0ZG (Abcam U-87MG MAPT KO)
CVCL_D1TJ (Abcam U-87MG MGLL KO)CVCL_D1TK (Abcam U-87MG MMP3 KO)CVCL_D1TL (Abcam U-87MG MMP9 KO)
CVCL_D1TM (Abcam U-87MG NCAM1 KO)CVCL_D1TN (Abcam U-87MG NCSTN KO)CVCL_D1TP (Abcam U-87MG NEO1 KO)
CVCL_D1TQ (Abcam U-87MG NFE2L2 KO)CVCL_D1TR (Abcam U-87MG NPTX1 KO)CVCL_D1TS (Abcam U-87MG NRP2 KO)
CVCL_D1TT (Abcam U-87MG NTRK2 KO)CVCL_D1TU (Abcam U-87MG NTRK3 KO)CVCL_D1TV (Abcam U-87MG PARK7 KO)
CVCL_D1TW (Abcam U-87MG PDE5A KO)CVCL_D1TX (Abcam U-87MG PEA15 KO)CVCL_D1TY (Abcam U-87MG PLA2G6 KO)
CVCL_D1TZ (Abcam U-87MG PLAUR KO)CVCL_D1U0 (Abcam U-87MG PLXNB2 KO)CVCL_D1U1 (Abcam U-87MG PML KO)
CVCL_D1U2 (Abcam U-87MG PRKCA KO)CVCL_D1U3 (Abcam U-87MG PRKCD KO)CVCL_D1U4 (Abcam U-87MG PRKCG KO)
CVCL_D1U5 (Abcam U-87MG RAB39B KO)CVCL_D1U6 (Abcam U-87MG RAB8A KO)CVCL_D1U7 (Abcam U-87MG ROBO1 KO)
CVCL_D1U8 (Abcam U-87MG RUNx1 KO)CVCL_D1U9 (Abcam U-87MG SCARB2 KO)CVCL_D1UA (Abcam U-87MG SCG2 KO)
CVCL_D1UB (Abcam U-87MG SDHB KO)CVCL_D1UC (Abcam U-87MG SERPINB2 KO)CVCL_D1UD (Abcam U-87MG SERPINE1 KO)
CVCL_D1UE (Abcam U-87MG SFRP1 KO)CVCL_D1UF (Abcam U-87MG SLC2A3 KO)CVCL_D1UG (Abcam U-87MG SLC6A4 KO)
CVCL_D1UH (Abcam U-87MG SLIT2 KO)CVCL_C0BJ (Abcam U-87MG SNCA KO)CVCL_D1UI (Abcam U-87MG SQSTM1 KO)
CVCL_D1UJ (Abcam U-87MG STMN1 KO)CVCL_D1UK (Abcam U-87MG TBX2 KO)CVCL_D1UL (Abcam U-87MG TH KO)
CVCL_D1UM (Abcam U-87MG TLR4 KO)CVCL_D1UN (Abcam U-87MG TNC KO)CVCL_D1UP (Abcam U-87MG TNFAIP3 KO)
CVCL_D1UQ (Abcam U-87MG TRPM8 KO)CVCL_D1UR (Abcam U-87MG TSPO KO)CVCL_D1US (Abcam U-87MG TUBB3 KO)
CVCL_D1UT (Abcam U-87MG UBE3A KO)CVCL_D1UU (Abcam U-87MG UCHL1 KO)CVCL_D1UV (Abcam U-87MG VCAN KO)
CVCL_D1UW (Abcam U-87MG VIM KO)CVCL_D1UX (Abcam U-87MG VLDLR KO)CVCL_C8WL (U-87 MG-EGFP)
CVCL_C8WM (U-87 MG-Luc)CVCL_5J15 (U-87 MG-luc2)CVCL_UR33 (U-87 MG-Luc2)
CVCL_UE09 (U-87MG ATCC IDH1 p.R132H)CVCL_C6JA (U-87MG ATCC ECE1 KO)CVCL_C3IF (U-87MG-parkin clone 19)
CVCL_C3IG (U-87MG-parkin clone 25)CVCL_C3IE (U-87MG-parkin clone 7)CVCL_VL16 (U-87MG/DDP)
CVCL_5J12 (U87 MG-Red-FLuc)CVCL_X702 (U87-CD4 clone 2)CVCL_C9F7 (U87-MG/Cas9 AAVS1)
CVCL_4V16 (U87-MG/Pt)CVCL_X626 (U87.CD4)CVCL_3428 (U87/DK)
CVCL_3429 (U87/WT)CVCL_A5CL (U87DND)CVCL_XZ66 (U87MG Human EGFR vIII)
CVCL_JY78 (U87MG.deltaEGFR)CVCL_JY80 (U87MG.DY1)CVCL_JY81 (U87MG.DY2)
CVCL_JY82 (U87MG.DY3)CVCL_JY83 (U87MG.DY4)CVCL_JY84 (U87MG.DY5)
CVCL_C6IK (U87MG/ALDH1A3-KO.1)CVCL_C6IL (U87MG/CPOX-KO)
Sex of cell Male
Age at sampling Age unspecified
Category Cancer cell line
STR profile Source(s): AddexBio; ATCC; CCRID; CLS; Cosmic-CLP; ECACC; Genomics_Center_BCF_Technion; KCLB; PubMed=11416159; PubMed=22570425; PubMed=25877200; PubMed=27582061

Markers:
AmelogeninX (AddexBio; CCRID; CLS; ECACC; Genomics_Center_BCF_Technion; PubMed=11416159; PubMed=22570425; PubMed=25877200; PubMed=27582061)
X,Y (ATCC; Cosmic-CLP; KCLB)
CSF1PO10,11
D1S165615
D2S44110,11
D2S133820,23
D3S135816,17
D5S81811,12
D7S8208,9
D8S117910,11
D10S124814
D12S39118,21
D13S3178,11
D16S53912
D18S5113 (CLS; PubMed=22570425)
13,14 (CCRID; Genomics_Center_BCF_Technion; PubMed=11416159; PubMed=25877200)
D19S43315,15.2
D21S1128,32.2
D22S104515,17
FGA18,24
Penta D9,14
Penta E7,14
TH019.3
TPOX8
vWA15,17

Run an STR similarity search on this cell line
Web pages https://en.wikipedia.org/wiki/U87
https://www.atcc.org/en/support/technical-support/faqs/atcc-htb-14-morphology-and-growth-conditions
https://www.synapse.org/#!Synapse:syn31544489
https://strap.nci.nih.gov/celline_detail.php?sample_id=58
https://www.proteinatlas.org/learn/cellines
http://genome.ucsc.edu/ENCODE/protocols/cell/human/U-87_Myers_protocol.pdf
https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/u/cell-lines-detail-314.html
https://iclac.org/wp-content/uploads/Cross-Contaminations_v12_distribution.xlsx
Publications

PubMed=327080; DOI=10.1093/jnci/59.1.221
Fogh J., Fogh J.M., Orfeo T.
One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice.
J. Natl. Cancer Inst. 59:221-226(1977)

PubMed=833871; DOI=10.1093/jnci/58.2.209
Fogh J., Wright W.C., Loveless J.D.
Absence of HeLa cell contamination in 169 cell lines derived from human tumors.
J. Natl. Cancer Inst. 58:209-214(1977)

PubMed=450131; DOI=10.1038/279797a0
Day R.S. III, Ziolkowski C.H.J.
Human brain tumour cell strains with deficient host-cell reactivation of N-methyl-N'-nitro-N-nitrosoguanidine-damaged adenovirus 5.
Nature 279:797-799(1979)

PubMed=22282976; DOI=10.1093/carcin/1.1.21
Day R.S. III, Ziolkowski C.H.J., Scudiero D.A., Meyer S.A., Mattern M.R.
Human tumor cell strains defective in the repair of alkylation damage.
Carcinogenesis 1:21-32(1980)

PubMed=7459858
Rousset M., Zweibaum A., Fogh J.
Presence of glycogen and growth-related variations in 58 cultured human tumor cell lines of various tissue origins.
Cancer Res. 41:1165-1170(1981)

PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)

PubMed=7763724
Satoh M., Takeuchi M.
Cross-contamination of cell lines as revealed by DNA fingerprinting in the IFO animal cell bank.
Res. Commun. Inst. Ferment. Osaka 16:18-23(1993)

PubMed=8069455; DOI=10.1007/BF02631450
Fukuchi K.-i., Hearn M.G., Deeb S.S., Smith A.C., Ngoc Thao D., Miyazaki J.-i., Bothwell M., Martin G.M.
Activity assays of nine heterogeneous promoters in neural and other cultured cells.
In Vitro Cell. Dev. Biol. Anim. 30:300-305(1994)

PubMed=9090379; DOI=10.1038/ng0497-356
Steck P.A., Pershouse M.A., Jasser S.A., Yung W.-K.A., Lin H., Ligon A.H., Langford L.A., Baumgard M.L., Hattier T., Davis T., Frye C., Hu R., Swedlund B., Teng D.H.-F., Tavtigian S.V.
Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers.
Nat. Genet. 15:356-362(1997)

PubMed=9230885; DOI=10.1093/jnci/89.14.1036
Gomez-Manzano C., Fueyo J., Kyritsis A.P., McDonnell T.J., Steck P.A., Levin V.A., Yung W.-K.A.
Characterization of p53 and p21 functional interactions in glioma cells en route to apoptosis.
J. Natl. Cancer Inst. 89:1036-1044(1997)

PubMed=9842975; DOI=10.1002/(SICI)1097-0215(19981218)79:6<640::AID-IJC15>3.0.CO;2-z
Weller M., Rieger J., Grimmel C., Van Meir E.G., De Tribolet N., Krajewski S., Reed J.C., von Deimling A., Dichgans J.
Predicting chemoresistance in human malignant glioma cells: the role of molecular genetic analyses.
Int. J. Cancer 79:640-644(1998)

PubMed=10074188; DOI=10.1128/JVI.73.4.3338-3350.1999
Arbour N., Cote G., Lachance C., Tardieu M., Cashman N.R., Talbot P.J.
Acute and persistent infection of human neural cell lines by human coronavirus OC43.
J. Virol. 73:3338-3350(1999)

PubMed=10402232; DOI=10.3892/ijo.15.2.237
Sharif T.R., Sharif M.
Overexpression of protein kinase C epsilon in astroglial brain tumor derived cell lines and primary tumor samples.
Int. J. Oncol. 15:237-243(1999)

PubMed=10416987; DOI=10.1111/j.1750-3639.1999.tb00536.x
Ishii N., Maier D., Merlo A., Tada M., Sawamura Y., Diserens A.-C., Van Meir E.G.
Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines.
Brain Pathol. 9:469-479(1999)

PubMed=10560660; DOI=10.1097/00005072-199911000-00007
Schmidt E.E., Ichimura K., Goike H.M., Moshref A., Liu L., Collins V.P.
Mutational profile of the PTEN gene in primary human astrocytic tumors and cultivated xenografts.
J. Neuropathol. Exp. Neurol. 58:1170-1183(1999)

PubMed=11414198; DOI=10.1007/s004320000207
Lahm H., Andre S., Hoeflich A., Fischer J.R., Sordat B., Kaltner H., Wolf E., Gabius H.-J.
Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures.
J. Cancer Res. Clin. Oncol. 127:375-386(2001)

PubMed=11416159; DOI=10.1073/pnas.121616198
Masters J.R.W., Thomson J.A., Daly-Burns B., Reid Y.A., Dirks W.G., Packer P., Toji L.H., Ohno T., Tanabe H., Arlett C.F., Kelland L.R., Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.
Short tandem repeat profiling provides an international reference standard for human cell lines.
Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001)

PubMed=11966317; DOI=10.1667/0033-7587(2002)157[0516:LDRHIH]2.0.CO;2
Chandna S., Dwarakanath B.S.R., Khaitan D., Mathew T.L., Jain V.
Low-dose radiation hypersensitivity in human tumor cell lines: effects of cell-cell contact and nutritional deprivation.
Radiat. Res. 157:516-525(2002)

PubMed=14614447; DOI=10.1038/sj.onc.1207198
Wischhusen J., Naumann U., Ohgaki H., Rastinejad F., Weller M.
CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death.
Oncogene 22:8233-8245(2003)

PubMed=14655754; DOI=10.1111/j.1750-3639.2003.tb00479.x
Bahr O., Rieger J., Duffner F., Meyermann R., Weller M., Wick W.
P-glycoprotein and multidrug resistance-associated protein mediate specific patterns of multidrug resistance in malignant glioma cell lines, but not in primary glioma cells.
Brain Pathol. 13:482-494(2003)

PubMed=14961077; DOI=10.1038/sj.onc.1207244
Wang Y.-L., Zhu S.-J., Cloughesy T.F., Liau L.M., Mischel P.S.
p53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibition.
Oncogene 23:1283-1290(2004)

PubMed=16232199; DOI=10.1111/j.1349-7006.2005.00099.x
Saigusa K., Hashimoto N., Tsuda H., Yokoi S., Maruno M., Yoshimine T., Aoyagi M., Ohno K., Imoto I., Inazawa J.
Overexpressed Skp2 within 5p amplification detected by array-based comparative genomic hybridization is associated with poor prognosis of glioblastomas.
Cancer Sci. 96:676-683(2005)

PubMed=16697959; DOI=10.1016/j.ccr.2006.03.030
Lee J., Kotliarova S., Kotliarov Y., Li A.-G., Su Q., Donin N.M., Pastorino S., Purow B.W., Christopher N., Zhang W., Park J.K., Fine H.A.
Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines.
Cancer Cell 9:391-403(2006)

PubMed=17595512; DOI=10.1159/000104150
Rieger J., Frank B., Weller M., Wick W.
Mechanisms of resistance of human glioma cells to Apo2 ligand/TNF-related apoptosis-inducing ligand.
Cell. Physiol. Biochem. 20:23-34(2007)

PubMed=19365568; DOI=10.1371/journal.pone.0005209
Bax D.A., Little S.E., Gaspar N., Perryman L., Marshall L., Viana-Pereira M., Jones T.A., Williams R.D., Grigoriadis A., Vassal G., Workman P., Sheer D., Reis R.M., Pearson A.D.J., Hargrave D., Jones C.
Molecular and phenotypic characterisation of paediatric glioma cell lines as models for preclinical drug development.
PLoS ONE 4:E5209-E5209(2009)

PubMed=19435942; DOI=10.1215/15228517-2009-025
Ichimura K., Pearson D.M., Kocialkowski S., Backlund L.M., Chan R., Jones D.T.W., Collins V.P.
IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas.
Neuro-oncol. 11:341-347(2009)

PubMed=20126413; DOI=10.1371/journal.pgen.1000832
Clark M.J., Homer N., O'Connor B.D., Chen Z.-G., Eskin A., Lee H., Merriman B., Nelson S.F.
U87MG decoded: the genomic sequence of a cytogenetically aberrant human cancer cell line.
PLoS Genet. 6:E1000832-E1000832(2010)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=20587068; DOI=10.1186/1471-2407-10-339
Nakabayashi H., Yawata T., Shimizu K.
Anti-invasive and antiangiogenic effects of MMI-166 on malignant glioma cells.
BMC Cancer 10:339.1-339.9(2010)

PubMed=20593219; DOI=10.1007/s11060-010-0283-9
Blough M.D., Beauchamp D.C., Westgate M.R., Kelly J.J.P., Cairncross J.G.
Effect of aberrant p53 function on temozolomide sensitivity of glioma cell lines and brain tumor initiating cells from glioblastoma.
J. Neurooncol. 102:1-7(2011)

PubMed=21406405; DOI=10.1158/0008-5472.CAN-10-3112
Grzmil M., Morin P. Jr., Lino M.M., Merlo A., Frank S., Wang Y.-H., Moncayo G., Hemmings B.A.
MAP kinase-interacting kinase 1 regulates SMAD2-dependent TGF-beta signaling pathway in human glioblastoma.
Cancer Res. 71:2392-2402(2011)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=22570425; DOI=10.1093/neuonc/nos072
Bady P., Diserens A.-C., Castella V., Kalt S., Heinimann K., Hamou M.-F., Delorenzi M., Hegi M.E.
DNA fingerprinting of glioma cell lines and considerations on similarity measurements.
Neuro-oncol. 14:701-711(2012)

PubMed=23325432; DOI=10.1101/gr.147942.112
Varley K.E., Gertz J., Bowling K.M., Parker S.L., Reddy T.E., Pauli-Behn F., Cross M.K., Williams B.A., Stamatoyannopoulos J.A., Crawford G.E., Absher D.M., Wold B.J., Myers R.M.
Dynamic DNA methylation across diverse human cell lines and tissues.
Genome Res. 23:555-567(2013)

PubMed=25960936; DOI=10.4161/21624011.2014.954893
Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
OncoImmunology 3:e954893.1-e954893.12(2014)

PubMed=25984343; DOI=10.1038/sdata.2014.35
Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S., East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H., Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M., Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S., Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D., Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C., Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P., Golub T.R., Root D.E., Hahn W.C.
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Sci. Data 1:140035-140035(2014)

PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)

PubMed=25894527; DOI=10.1371/journal.pone.0121314
Bausch-Fluck D., Hofmann A., Bock T., Frei A.P., Cerciello F., Jacobs A., Moest H., Omasits U., Gundry R.L., Yoon C., Schiess R., Schmidt A., Mirkowska P., Hartlova A.S., Van Eyk J.E., Bourquin J.-P., Aebersold R., Boheler K.R., Zandstra P.W., Wollscheid B.
A mass spectrometric-derived cell surface protein atlas.
PLoS ONE 10:E0121314-E0121314(2015)

PubMed=26496030; DOI=10.18632/oncotarget.6171
Patil V., Pal J., Somasundaram K.
Elucidating the cancer-specific genetic alteration spectrum of glioblastoma derived cell lines from whole exome and RNA sequencing.
Oncotarget 6:43452-43471(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=27412690; DOI=10.1074/mcp.M116.060350
Shraibman B., Kadosh D.M., Barnea E., Admon A.
Human leukocyte antigen (HLA) peptides derived from tumor antigens induced by inhibition of DNA methylation for development of drug-facilitated immunotherapy.
Mol. Cell. Proteomics 15:3058-3070(2016)

PubMed=27582061; DOI=10.1126/scitranslmed.aaf6853
Allen M., Bjerke M., Edlund H., Nelander S., Westermark B.
Origin of the U87MG glioma cell line: good news and bad news.
Sci. Transl. Med. 8:354re3.1-354re3.4(2016)

PubMed=27894925; DOI=10.1016/j.bbagen.2016.11.033
Casasampere M., Ordonez Y.F., Casas J., Fabrias G.
Dihydroceramide desaturase inhibitors induce autophagy via dihydroceramide-dependent and independent mechanisms.
Biochim. Biophys. Acta 1861:264-275(2017)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=30971826; DOI=10.1038/s41586-019-1103-9
Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M., Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R., Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P., van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L., Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Nature 568:511-516(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=31978347; DOI=10.1016/j.cell.2019.12.023
Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III, Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K., Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P.
Quantitative proteomics of the Cancer Cell Line Encyclopedia.
Cell 180:387-402.e16(2020)

PubMed=33385022; DOI=10.1016/j.dib.2020.106643
de Sousa J.F., da Silva P., Serafim R.B., Nociti R.P., Moreira C.G., Silva W.A., Valente V.
RNA sequencing data of different grade astrocytoma cell lines.
Data Brief 34:106643.1-106643.13(2021)

Cross-references
Cell line collections (Providers) Abcam; ab278079
AddexBio; C0005002/71
ATCC; HTB-14
BCRC; 60360
BCRJ; 0241
CCTCC; GDC0157
CLS; 300367
ECACC; 89081402
HIVReagentProgram; ARP-2188
IBRC; C10982
ICLC; HTL00013
IZSLER; BS TCL 189
KCB; KCB 2011101YJ
KCLB; 30014
NCBI_Iran; C531
RCB; RCB0419 - Discontinued
Ubigene; YC-C028
Cell line databases/resources CLO; CLO_0009463
CLO; CLO_0009464
MCCL; MCC:0000469
CLDB; cl4592
CLDB; cl4594
CLDB; cl4595
CLDB; cl7166
cancercelllines; CVCL_0022
CCRID; 1101HUM-PUMC000208
CCRID; 3101HUMTCHu138
Cell_Model_Passport; SIDM01189
CGH-DB; 157-1
Cosmic-CLP; 687590
DepMap; ACH-000075
LINCS_HMS; 50868
LINCS_LDP; LCL-1364
Lonza; 37
Lonza; 808
TOKU-E; 3381
Anatomy/cell type resources BTO; BTO:0002036
Biological sample resources BioSample; SAMN03472715
BioSample; SAMN03473126
BioSample; SAMN05292456
BioSample; SAMN07710026
BioSample; SAMN07710027
BioSample; SAMN07710028
BioSample; SAMN07710029
BioSample; SAMN07710030
BioSample; SAMN07710031
BioSample; SAMN07710032
BioSample; SAMN10988360
ENCODE; ENCBS424ENC
CRISP screens repositories BioGRID_ORCS_Cell_line; 348
Chemistry resources ChEMBL-Cells; CHEMBL3307575
ChEMBL-Cells; CHEMBL3989361
ChEMBL-Targets; CHEMBL614247
GDSC; 687590
PharmacoDB; U87MG_1623_2019
PubChem_Cell_line; CVCL_0022
Encyclopedic resources Wikidata; Q7863603
Experimental variables resources EFO; EFO_0005237
Gene expression databases ArrayExpress; E-MTAB-783
ArrayExpress; E-MTAB-2770
ArrayExpress; E-MTAB-3610
GEO; GSM101687
GEO; GSM101688
GEO; GSM101676
GEO; GSM101686
GEO; GSM326243
GEO; GSM481417
GEO; GSM500897
GEO; GSM887723
GEO; GSM888817
GEO; GSM923437
GEO; GSM1374974
GEO; GSM1638668
GEO; GSM1670559
GEO; GSM2113436
GEO; GSM2113437
GEO; GSM2113438
GEO; GSM2113439
Polymorphism and mutation databases Cosmic; 687590
Cosmic; 849853
Cosmic; 850741
Cosmic; 850822
Cosmic; 920816
Cosmic; 1036336
Cosmic; 1064099
Cosmic; 1066234
Cosmic; 1171224
Cosmic; 1175825
Cosmic; 1198263
Cosmic; 1217671
Cosmic; 1219449
Cosmic; 1237542
Cosmic; 1294951
Cosmic; 1610737
Cosmic; 1746951
Cosmic; 1945859
Cosmic; 2302316
Cosmic; 2367555
Cosmic; 2491106
Cosmic; 2516044
Cosmic; 2550364
Cosmic; 2568870
Cosmic; 2580918
Cosmic; 2701083
IARC_TP53; 21096
LiGeA; CCLE_552
Progenetix; CVCL_0022
Proteomic databases PRIDE; PXD000589
PRIDE; PXD000661
PRIDE; PXD001565
PRIDE; PXD003790
Sequence databases EGA; EGAS00001000978
Entry history
Entry creation04-Apr-2012
Last entry update30-Jan-2024
Version number45